Spontaneous Bacterial Peritonitis
Conditions
Brief summary
Study Design: Double-blind placebo-controlled clinical trial Study Duration:2 years Study Center: Hospital de la Santa Creu i Sant Pau, Barcelona (single center) Objectives: To assess the effect of adjunctive Vivomixx® on bacterial translocation in patients with cirrhosis and SBP Number of Subjects: 30 Main Inclusion Criteria: Patients with cirrhosis hospitalized with an episode of SBP at Hospital de la Santa Creu i Sant Pau Study Product, Dose, Route, Regimen: Vivomixx ® sachets containing 450 x 109 bacteria, 2 every 12 hours during hospitalization (n=15), or placebo (n=15) Duration of administration: During hospitalization due to SBP episode Hypothesis: The adjunctive treatment with Vivomixx® in patients with cirrhosis and SBP could decrease bacterial translocation and systemic and cerebral proinflammatory state. This would result in a faster SBP resolution, a decrease in the incidence of complications and an improvement in cognitive function.
Interventions
DRUGVivomixx®
Vivomixx® is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) and lactobacilli (L. paracasei DSM 24733, L. acidophilus DSM 24735, L. delbrueckii subsp bulgaricus DSM 24734, L. plantarum DSM 24730). The active agent will be supplied as a 4.4g sachet at a dose of 450 billion live bacteria per sachet with maltose and silicon dioxide as excipients.
DRUGPlacebo
Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
Sponsors
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with cirrhosis hospitalized with an episode of SBP at Hospital de la Santa Creu i Sant Pau. Cirrhosis will be diagnosed by clinical, analytical and ultrasonographic findings or by liver biopsy. SBP will be diagnosed by an ascitic fluid neutrophil count \> 250/mm3 with or without positive culture .
Exclusion criteria
* Advanced hepatocellular carcinoma (beyond Milan's criteria) or any other malignancy. * Advanced liver insufficiency \[MELD (model for end-stage liver disease) \>25\]. * Active alcohol intake (in the previous 3 months). * Neurological disease. * Marked symptomatic comorbidities (cardiac, pulmonary, renal, untreated active depression, HIV infection). * Previous antibiotic treatment, including norfloxacin and rifaximin. * Septic shock, ileus, need for tracheal intubation or intensive care unit. * Immunomodulatory drugs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in bacterial translocation (composite measure) | At baseline, daily until infection resolution (an expected average of 7 days) and at three months after discharge | Bacterial translocation will be evaluated by change from baseline in bacterial DNA in blood and ascitic fluid, lipopolysaccharide binding protein (LBP), intestinal fatty acid-binding protein (I-FABP) and intestinal bile acid binding protein (I-BABP) in blood, and polyethylene glycols (PEG) and claudin 3 in urine . |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in systemic inflammatory response and systemic oxidative damage (composite measure) | At baseline, daily until infection resolution (an expected average of 7 days) and at three months after discharge | Systemic Inflammation and immune response will be evaluated by change from baseline in serum C reactive protein (CRP), interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, IL-10, IL-12, IL-18, IL-22, sTNFR-1, sTNFR-2, sCD163, matrix metalloproteinase (MMP) -9, interferon (IFN)-γ, vascular endothelial growth factor (VEGF), claudin-5, nitrites and nitrates in serum and ascitic fluid. Systemic oxidative damage will be evaluated by change from baseline in determination of malondialdehyde (MDA) in blood. |
| Changes in cognitive function (composite measure) | At baseline at infection resolution (an expected average of 7 days) | Cognitive function will be evaluated by change from baseline in Trail-Making Test A (TMT-A), Trail-Making Test B (TMT-B), and Digit Symbol Test (DST). |
| Changes in brain inflammation (composite measure) | At baseline (during the first 12-24 hours after inclusion in the study) and after 3 days of treatment. | Brain inflammation will be evaluated by change from baseline in MRI and different biomarkers of neuroinflammation. A designed MR protocol will be produced, including imaging using different sequences, and more biochemical (MR spectroscopy) and functional (DTI) studies. |
Countries
Spain
Outcome results
None listed